Unless otherwise defined, all abbreviations used herein shall have the same meaning as those defined in the Company’s announcements dated 10 May 2024, 14 May 2024 and 30 September 2024 in relation to the Proposed Transfer of Listing (“Announcements”).

Reference is made to the Announcements.

On behalf of the Board, M&A Securities wishes to announce that Bursa Securities had vide its letter dated 7 January 2025, resolved the following:

(a) to approve the proposed transfer of listing of Fibromat from the LEAP Market to the ACE Market of Bursa Securities and quotation for the entire enlarged issued share capital of Fibromat comprising 248,276,000 shares of Fibromat on the ACE Market of Bursa Securities;

(b) to grant approval-in-principle for registration of the listing prospectus of Fibromat. In this regard, M&A Securities is required to provide a confirmation of registration at least 7 market days prior to the intended date of registration; and

(c) to grant a waiver to the Company from complying with Rule 3.19A of the AMLR.

Fibromat and/or M&A Securities are required to comply with the following:

(a) Submission of the following information with respect to the moratorium on the shareholdings of the specified shareholders to Bursa Malaysia Depository Sdn Bhd:

(i) Name of shareholders;

(ii) Number of shares; and

(iii) Date of expiry of the moratorium for each block of shares.

(b) Approvals from other relevant authorities have been obtained for implementation of the Proposed Transfer of Listing;

(c) The Bumiputera equity requirements for public listed companies as approved/exempted by the Securities Commission Malaysia including any conditions imposed thereon;

(d) Make the relevant announcements pursuant to Paragraphs 8.1 and 8.2 of Guidance Notes 15 of the AMLR;

(e) Furnish to Bursa Securities a copy of the schedule of distribution showing compliance with the public shareholding spread requirements based on the entire issued share capital of the Company on the first day of listing on the ACE Market;

(f) In relation to the public offering to be undertaken by the Company, to announce at least 2 market days prior to the listing date, the result of the offering including the following:

(i) Level of subscription of public balloting and placement;

(ii) Basis of allotment/allocation;

(iii) A table showing the distribution for placement tranche as per the format prescribed in Bursa Securities’ approval letter; and

(iv) Disclosure of placees who become substantial shareholders of the Company arising from the public offering, if any.

M&A Securities must ensure that the overall distribution of the Company’s securities is properly carried out to mitigate any disorderly trading in the secondary market; and

(g) Fibromat or M&A Securities to furnish Bursa Securities with a written confirmation of its compliance with the terms and conditions of Bursa Securities’ approval upon the admission of the Company to the Official List of the ACE Market.

Fibromat and M&A Securities are required to ensure full compliance with all requirements as provided under the AMLR at all times.

This announcement is dated 8 January 2025.